Advertisement

Funktionelle Durchblutungsstörungen

Chapter
  • 170 Downloads
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Den Begriff funktionelle Durchblutungsstörungen verwendet man für Krankheitsbilder, bei denen es zu einer Engstellung oder Erweiterung der Gefäße kommt, ohne dass organische Gefäßveränderungen vorhanden sind.

Literatur

  1. Allen EV, Brown GE (1932) Raynaud’s disease: a critical review of minimal requisites for diagnosis. Am J Med Sci 183(2):187–200CrossRefGoogle Scholar
  2. Baldwin ZK, Ceraldi CC (2003) Ergotism associated with HIV antiviral protease inhibitor therapy. J Vasc Surg 37(3):676–678CrossRefGoogle Scholar
  3. Belch JJ, Newman P, Drury JK, McKenzie F, Capell H, Leiberman P, Forbes CD, Prentice CR (1983) Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud’s syndrome: a double-blind controlled trial. Lancet 1:313–315CrossRefGoogle Scholar
  4. Bettoni L, Geri A, Airo P, Danieli E, Cavazzana I, Antonioli C, Chiesa L, Franceschini F, Grottolo A, Zambruni A, Radaeli E, Cattaneo R (2002) Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 21(3):244–250CrossRefGoogle Scholar
  5. Bollinger A, Schlumpf M (1976) Finger blood flow in healthy subjects of different age and sex and in patients with primary Raynaud’s disease. Acta Chir Scand Suppl 465:42–47PubMedGoogle Scholar
  6. Bollinger A, Mahler F, Meier B (1977) Velocity patterns in nailfold capillaries of normal subjects and patients with Raynaud’s disease and acrocyanosis. Bibl Anat 16:142–145Google Scholar
  7. Caglayan E, Huntgeburth M, Karasch T, Weihrauch J, Hunzelmann N, Krieg T, Erdmann E, Rosenkranz S (2006) Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud’s disease. Arch Intern Med 166(2):231–233CrossRefGoogle Scholar
  8. Coffman JD, Cohen RA (1988) Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits. Eur J Clin Invest 18(3):309–313CrossRefGoogle Scholar
  9. Dowd PM, Martin MF, Cooke ED, Bowcock SA, Jones R, Dieppe PA, Kirby JD (1982) Treatment of Raynaud’s phenomenon by intravenous infusion of prostacyclin (PGI2). Br J Dermatol 106(1):81–89CrossRefGoogle Scholar
  10. Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, Black CM (1999) Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42(12):2646–2655CrossRefGoogle Scholar
  11. Eadie MJ (2001) Clinically significant drug interactions with agents specific for migraine attacks. CNS Drugs 15(2):105–118CrossRefGoogle Scholar
  12. El Menyar AA (2006) Drug-induced myocardial infarction secondary to coronary artery spasm in teenagers and young adults. J Postgrad Med 52(1):51–56PubMedGoogle Scholar
  13. Friedman EA, Harris PA, Wood AJ, Stein CM, Kurnik D (2007) The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud’s phenomenon. Clin Pharmacol Ther 81(4):503–509CrossRefGoogle Scholar
  14. Fries R, Shariat K, von Wilmowsky H, Bohm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985CrossRefGoogle Scholar
  15. Gardinali M, Pozzi MR, Bernareggi M, Montani N, Allevi E, Catena L, Cugno M, Bottasso B, Stabilini R (2001) Treatment of Raynaud’s phenomenon with intravenous prostaglandin E1 alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis. J Rheumatol 28(4):786–794PubMedGoogle Scholar
  16. Herskowitz MM, Gillego V, Ward M, Wright G (2002) Cocaine-induced mesenteric ischemia: treatment with intra-arterial papaverine. Emerg Radiol 9(3):172–174CrossRefGoogle Scholar
  17. Hirschl M, Katzenschlager R, Francesconi C, Kundi M (2004) Low level laser therapy in primary Raynaud’s phenomenon – results of a placebo controlled, double blind intervention study. J Rheumatol 31(12):2408–2412PubMedGoogle Scholar
  18. Husmann MJ, Barton M, Jacomella V, Silvestro V, Amann-Vesti B (2006) Long-term effects of endovascular angioplasty on orthostatic vasocutaneous autoregulation in patients with peripheral atherosclerosis. J Vasc Surg 44(5):993–997CrossRefGoogle Scholar
  19. Jamieson GG, Ludbrook J, Wilson A (1971) Cold hypersensitivity in Raynaud’s phenomenon. Circulation 44:254–264CrossRefGoogle Scholar
  20. Kuhnert SM, Phillips WJ, Davis MD (1999) Lidocaine and mexiletine therapy for erythromelalgia. Arch Dermatol 135(12):1447–1449CrossRefGoogle Scholar
  21. Kyle MV, Belcher G, Hazleman BL (1992) Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud’s phenomenon. J Rheumatol 19(9):1403–1406PubMedGoogle Scholar
  22. LeRoy EC, Medsger TA (1992) Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol 10(5):485–488PubMedGoogle Scholar
  23. Levien TL (2006) Phosphodiesterase inhibitors in Raynaud’s phenomenon. Ann Pharmacother 40(7–8):1388–1393CrossRefGoogle Scholar
  24. Maga P, Kuzdzal J, Nizankowski R, Szczeklik A, Sladek K (2007) Long-term effects of thoracic sympathectomy on microcirculation in the hands of patients with primary Raynaud disease. J Thorac Cardiovasc Surg 133(6):1428–1433CrossRefGoogle Scholar
  25. Mahler F, Meier B, Frey R, Bollinger A, Anliker M (1977) Reaction of red blood cell velocity in nailfold capillaries to local cold in patients with vasospastic disease. Bibl Anat 16:155–158Google Scholar
  26. Mahler F, Saner H, Boss CH, Annaheim M (1987) Local cold exposure for capillaroscopic examination of patients with Raynaud’s syndrome. Microvasc Res 33:422–427CrossRefGoogle Scholar
  27. Maricq HR, Spencer-Green G, LeRoy EC (1975) Abnormal capillary patterns and systemic disease in scleroderma (progressive systemic sclerosis). Bibl Anat 13:248–249PubMedGoogle Scholar
  28. Maricq HR, LeRoy EC, D'Angelo WA, Medsger TA, Rodnan GP, Sharp GC, Wolfe JF (1980) Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 23(2):183–189CrossRefGoogle Scholar
  29. Meli M, Gitzelmann G, Koppensteiner R, Amann-Vesti BR (2006) Predictive value of nailfold capillaroscopy in patients with Raynaud’s phenomenon. Clin Rheumatol 25(2):153–158CrossRefGoogle Scholar
  30. Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, Kirby JD (1989) Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud’s phenomenon in patients with systemic sclerosis: a double blind randomized study. BMJ 298:561–564CrossRefGoogle Scholar
  31. Riccardi MT, Chialà A, Lannone F, Grattagliano V, Covelli M, Lapadula G (2007) Treatment of digital ulcers in systemic sclerosis with endothelin-1 receptor antagonist (bosentan). Reumatismo 59(2):135–139PubMedGoogle Scholar
  32. Rusch NJ, Shepherd JT, Vanhoutte PM (1981) The effect of profound cooling on adrenergic neurotransmission in canine cutaneous veins. J Physiol 311:57–65CrossRefGoogle Scholar
  33. Rustin MH, Almond NE, Beacham JA, Brooks RJ, Jones DP, Cooke ED, Dowd PM (1987) The effect of captopril on cutaneous blood flow in patients with primary Raynaud’s phenomenon. Br J Dermatol 117(6):751–758CrossRefGoogle Scholar
  34. Smith CD, McKendry RVR (1982) Controlled trial of nifedipine in the treatment of Raynaud’s phenomon. Lancet 2:1299–1301CrossRefGoogle Scholar
  35. Tosi S, Marchesoni A, Messina K, Bellintani C, Sironi G, Faravelli C (1987) Treatment of Raynaud’s phenomenon with captopril. Drugs Exp Clin Res 13(1):37–42PubMedGoogle Scholar
  36. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, Steen VD, Varga J, Jimenez S, Mayes M, Clements PJ, Weiner SR, Porter J, Ellman M, Wise C, Kaufman LD, Williams J, Dole W (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120(3):199–206CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2020

Authors and Affiliations

  1. 1.Universitätsspital ZürichZürichSchweiz

Personalised recommendations